Pharmaceutical giant Novo Nordisk has announced a €432 million investment to expand its manufacturing facility in Athlone, Ireland, a move aimed at increasing production capacity for the company’s growing portfolio of GLP-1 treatments. The investment, equivalent to approximately DKK 3.2 billion, will upgrade the company’s tabletting facility located in Monksland, a suburb of Athlone.
The project is expected to significantly strengthen Novo Nordisk’s global manufacturing network and help meet rising demand for oral therapies targeting chronic diseases such as diabetes and obesity. The expansion will focus on increasing the facility’s ability to produce oral GLP-1 medications, an important and rapidly expanding category of treatments used to manage metabolic disorders.
According to the company, the investment will fund upgrades and retrofitting of the existing facility, allowing it to manufacture both current and future oral GLP-1 medicines. The improvements are designed to enhance manufacturing efficiency, strengthen supply reliability, and support the company’s strategy to expand access to these therapies worldwide.
Novo Nordisk executives described the investment as a major milestone for the company’s operations in Ireland. The expanded facility will serve as an important hub for supplying markets outside the United States, reinforcing Ireland’s role in the company’s global production network.
Kasper Bødker Mejlvang, executive vice president for CMC and Product Supply at Novo Nordisk, said the investment reflects the company’s commitment to scaling up production of oral therapies to meet both current and future demand. He emphasized that the Athlone expansion will help the company continue delivering innovative treatments to millions of people living with serious chronic diseases.
Novo Nordisk has maintained a significant presence in Ireland for decades, and the Athlone facility has become an important part of its manufacturing infrastructure. The site currently employs around 260 people who focus on producing high-quality oral medicines while maintaining efficient and environmentally sustainable production processes.
Beyond boosting production capacity, the expansion project is also expected to generate economic benefits for the local community. The construction phase alone is projected to create up to 500 jobs as contractors and construction teams work on the site upgrades.
The Athlone facility spans approximately 45 acres, or 18 hectares, and construction work has already begun. The upgrades and expansion will be completed gradually, with different phases scheduled to finish between the end of 2027 and 2028.
The investment comes amid rapidly growing global demand for GLP-1-based therapies, which have gained significant attention in recent years due to their effectiveness in treating diabetes and obesity. By strengthening its manufacturing capabilities, Novo Nordisk aims to ensure a stable supply of these medications while supporting future product launches.
Industry analysts note that the company’s decision to expand production capacity reflects both the increasing demand for GLP-1 therapies and the strategic importance of securing global manufacturing capabilities for next-generation metabolic disease treatments.
Once completed, the upgraded Athlone facility is expected to play a key role in supporting Novo Nordisk’s long-term strategy of expanding access to innovative medicines while continuing to advance global healthcare innovation.